Capsida Biotherapeutics Inc., a fully integrated biotechnology company creating a new class of targeted adeno-associated virus (AAV) gene therapies for patients with debilitating and life-threatening genetic disorders, has opened its state-of-the-art manufacturing facility in Thousand Oaks.   As a fully integrated gene therapy company, Capsida is unique in its end-to-end expertise – which includes AAV engineering, cargo development and optimization, translational biology, early capsid manufactur...